Black Diamond Therapeutics (BDTX)

$5.47

-0.5

(-8.38%)

Market is closed - opens 7 PM, 18 Jun 2024

Insights on Black Diamond Therapeutics

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 244.3% return, outperforming this stock by 298.2%

Performance

  • $5.33
    $6.00
    $5.47
    downward going graph

    2.49%

    Downside

    Day's Volatility :11.1%

    Upside

    8.83%

    downward going graph
  • $1.62
    $7.66
    $5.47
    downward going graph

    70.38%

    Downside

    52 Weeks Volatility :78.85%

    Upside

    28.59%

    downward going graph

Returns

PeriodBlack Diamond TherapeuticsSector (Health Care)Index (Russel 2000)
3 Months
27.02%
0.4%
0.0%
6 Months
113.21%
8.7%
0.0%
1 Year
195.54%
10.3%
0.0%
3 Years
-53.9%
16.5%
-22.7%

Highlights

Market Capitalization
347.2M
Book Value
$1.99
Earnings Per Share (EPS)
-1.66
Wall Street Target Price
12.6
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-38.27%
Return On Equity TTM
-78.81%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-84.7M
Diluted Eps TTM
-1.66
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.47
EPS Estimate Next Year
-1.67
EPS Estimate Current Quarter
-0.43
EPS Estimate Next Quarter
-0.43

Analyst Recommendation

Buy
    91%Buy
    8%Hold
    0
    0%Sell
Based on 12 Wall street analysts offering stock ratings for Black Diamond Therapeutics(by analysts ranked 0 to 5 stars)
Based on 12 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
11
11
11
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 130.35%

Current $5.47
Target $12.60

Technicals Summary

Sell

Neutral

Buy

Black Diamond Therapeutics is currently in a neutral trading position according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Black Diamond Therapeutics
Black Diamond Therapeutics
22.59%
113.21%
195.54%
-53.9%
-84.88%
Moderna, Inc.
Moderna, Inc.
5.36%
63.93%
12.72%
-30.84%
787.95%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
5.52%
21.82%
32.68%
93.38%
233.31%
Novo Nordisk A/s
Novo Nordisk A/s
8.04%
43.97%
76.29%
244.33%
458.71%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
7.98%
18.8%
40.28%
155.22%
176.63%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Black Diamond Therapeutics
Black Diamond Therapeutics
NA
NA
NA
-1.47
-0.79
-0.38
NA
1.99
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-6.71
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
30.32
30.32
1.46
44.13
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
49.73
49.73
2.36
3.47
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.07
31.07
0.53
17.09
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Black Diamond Therapeutics
Black Diamond Therapeutics
Buy
$347.2M
-84.88%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$55.7B
787.95%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$113.1B
233.31%
30.32
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$634.9B
458.71%
49.73
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$123.6B
176.63%
31.07
39.46%

Institutional Holdings

  • Bellevue Group AG

    15.14%
  • T. Rowe Price Investment Management,Inc.

    11.95%
  • NEA Management Company, LLC

    7.91%
  • RA Capital Management, LLC

    6.27%
  • Artal Group S A

    3.64%
  • Vanguard Group Inc

    3.39%

Company Information

black diamond therapeutics, inc., a precision oncology medicine company, discovers and develops small molecule, tumor-agnostic therapies. its lead product candidate is bdtx-189, an inhibitor of non-canonical and oncogenic mutations of erbb kinases epidermal growth factor receptor (egfr) and tyrosine-protein kinase. the company is also developing allosteric-egfr mutation inhibitors; and various early stage pipeline programs targeting allosteric mutations in kinases related to cancer and/or rare genetic diseases. the company was formerly known as aset therapeutics, inc. and changed its name to black diamond therapeutics, inc. in january 2018. black diamond therapeutics, inc. was founded in 2014 and is headquartered in cambridge, massachusetts.

Organization
Black Diamond Therapeutics
Employees
54
CEO
Dr. Mark A. Velleca M.D., Ph.D.
Industry
Health Technology

FAQs